Genome-wide association studies have revealed that the 16p13 chromosomal region, including CLEC16A, DEXI, CIITA and SOCS1, is associated with susceptibility to autoimmune diseases. As non-coding single-nucleotide polymorphisms (SNPs) may confer susceptibility to disease by affecting expression of nearby genes, we examined whether autoimmune-associated intronic CLEC16A SNPs (rs12708716, rs6498169 and rs7206912) correlate with the expression of CLEC16A itself as well as neighboring genes in wholeblood and thymic samples. Real-time quantitative PCR analyses show that SOCS1 and DEXI expression was lower in thymic samples carrying at least one of the CLEC16A risk alleles compared with non-carriers of the risk allele. Linear regression analysis revealed a significant correlation between the expression level of CLEC16A and that of SOCS1 and DEXI in thymic samples. These data indicate a possible regulatory role for multiple sclerosis-associated non-coding CLEC16A SNPs and a common control mechanism for the expression of CLEC16A, SOCS1 and DEXI.
INTRODUCTION
Polymorphisms in the C-type lectin domain family 16, member A (CLEC16A) gene on chromosome 16p13, influence susceptibility for development of several autoimmune disorders, including type 1 diabetes, [1] [2] [3] Addison's disease, 4 Crohn's disease 5 and multiple sclerosis (MS), 2, 6, 7 among others. [8] [9] [10] Fine mapping of 57 CLEC16A single-nucleotide polymorphisms (SNPs) in a combined British and Norwegian MS cohort revealed that rs12708716, which lies within intron 19 of CLEC16A, showed the strongest association to MS, followed by two other intronic CLEC16A SNPs, rs7206912 and rs6498169 (both in intron 22). 3, 11 Several recent studies, 2, 12, 13 including a collaborative genome-wide association study, which involved 9 772 MS cases and 17 376 controls, confirmed CLEC16A intron 19 (rs7200786, in linkage disequilibrium (LD) with rs12708716; D 0 ¼ 1, R 2 ¼ 0.61 (haploview v 4.2, CEU population)) as an MS susceptibility locus. 7 Although there are independent genetic signals from other genes in the 16p13 chromosomal region, for example, CIITA, SOCS1 and the intergenic CLEC16A-SOCS1 region, [14] [15] [16] [17] CLEC16A has been suggested to be the most likely candidate gene as it contains the strongest MS-associated SNPs. 17 Common for the autoimmune-associated CLEC16A SNPs is that they are located in non-coding regions of CLEC16A, [1] [2] [3] [4] [5] 7, 18 and it is uncertain whether these SNPs could influence expression of CLEC16A itself or its neighboring genes. We have previously shown an association between the CLEC16A rs12708716 genotype and the relative expression of two CLEC16A isoforms in samples from thymic tissue. 11 Recently, an expression quantitative trait locus for the neighboring DEXI gene was identified within intron 19 of CLEC16A in monocytes and in lymphoblastoid cell lines.
No expression quantitative trait locus were detected for other genes within the 16p13 region in these data sets. 19, 20 CLEC16A is widely expressed in immune cells (www.genome. ucsc.edu), but its immune function is still unknown. The presence of an immunoreceptor tyrosine-based activation motif (http:// elm.eu.org) indicates a potential role for CLEC16A in immune cell activation. In addition to CLEC16A itself, both CIITA and SOCS1 are attractive candidate genes for autoimmune disease, 4, 15, 21, 22 and their functions in immune cells are well established. CIITA encodes the major histocompatibility complex class II transactivator, a transcription factor required for the activation of the major histocompatibility complex class II gene expression.
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SOCS1 is a suppressor of cytokine signaling important for immune cell homeostasis and regulation of inflammation. 24 The DEXI gene, which is located between CIITA and CLEC16A (Figure 1a) , is a dexamethasone-induced gene with unknown function. 25 Whole-genome expression data have shown that expression of the adjacent DEXI, CLEC16A and SOCS1 genes are highly correlated in human lymphoblastoid cell lines, 17 but not in human monocytes. 19 In a previous report, we investigated the correlation between expression of two CLEC16A isoforms and the CLEC16A rs12708716 genotype in whole-blood as well as in thymic samples. 11 In the present report, we have extended these analyses to study gene expression of CLEC16A as well as selected neighboring genes, CIITA, DEXI and SOCS1, and tested for correlation with the presence of the three CLEC16A SNPs (rs12708716, rs7206912 and rs6498169) that displayed the strongest association with MS in our fine-mapping studies of 57 CLEC16A SNPs in a combined British and Norwegian cohort. 11 The presence of CLEC16A MS risk alleles correlated with reduced SOCS1 and DEXI expression, and linear regression analyses revealed that DEXI, CLEC16A and SOCS1 were co-expressed in thymic samples.
RESULTS AND DISCUSSION
Non-coding SNPs may confer susceptibility to disease development by affecting the expression of nearby genes in cis. 26, 27 As genetic variants can mediate tissue-dependent variations in gene expression, we analyzed the expression of CLEC16A itself and its nearby genes, CIITA, DEXI and SOCS1, both in whole-blood (n ¼ 24) and thymic tissue samples (n ¼ 37) using quantitative realtime PCR. These samples were genotyped for three CLEC16A SNPs, that is, rs12708716 (intron 19), rs6498169 and rs7206912 (both in intron 22), conferring the most significant CLEC16A associations to MS in a combined Norwegian and British cohort. 11 We found no significant CLEC16A genotype-dependent differences in CLEC16A, DEXI, SOCS1 or CIITA expression in the whole-blood samples (data not shown). Whole-blood samples are heterogeneous in their cell composition, so any cell-specific, genetically determined variation may be overshadowed by variations in the proportions of the various cell types.
Gene expression was then measured in the more homogenous thymic tissue samples, which consists primarily of T cells. For each genotype, we consistently grouped individuals homozygous for the CLEC16A risk allele together with individuals heterozygous for the risk allele, and compared with the individuals being homozygous for the protective allele. We observed a significantly lower SOCS1 expression in thymic samples carrying at least one CLEC16A risk allele ( Figure 2 , right diagrams). Similarly, DEXI expression was lower in the thymic tissue samples from individuals carrying the CLEC16A rs6498169 risk allele compared with non-carriers ( Figure 2b) . A similar trend for DEXI expression was observed also for the other two CLEC16A SNPs; however, this difference did not reach statistical significance, probably owing to the small sample size in the non-carrier group. These data clearly indicate that there is correlation between the given CLEC16A genotypes and DEXI and SOCS1 expression in thymic samples. We cannot rule out that the discrepancy between the results in whole-blood and in thymic samples might be owing to individual differences, as whole-blood and thymic samples are harvested from different donor groups of different age and health state. Lack of power could also explain the lack of correlation in the wholeblood samples. Permutation analyses using the R-software (R core team, Vienna, Austria, 2012) indicates that we have the power to detect a correlation in SOCS1 expression in samples sorted for the rs7206912 genotype (lower right graph in Figure 2 ). However, for the other tests giving significant correlation between gene expression and CLEC16A genotype in the thymic tissue, we lack power for the whole-blood samples (data not shown). Expression of total CLEC16A and CIITA was not affected by the CLEC16A genotype in thymic tissue (Figure 2) , which is in accordance with previous reports from us and others. 11, 17, 19 As we applied expression assays covering all the CIITA variants and the two long CLEC16A isoforms, we cannot exclude the possibility that disease-associated CLEC16A SNPs could affect the expression of particular isoforms of these genes. Of note, in a previous paper, 11 CLEC16A expression was measured in the same thymic tissue samples. In this previous study, the grouping of the samples was different; individuals homozygous for the risk allele were compared with non-risk homozygotes carriers grouped together with heterozygotes. When we compared CIITA, DEXI, CLEC16A (both isoforms) and SOCS1 gene expression in these groups, no significant correlation with genotype was found. However, there was a trend toward higher DEXI and SOCS1 expression in the non-risk carrier group, which did not reach statistical significance (data not shown).
A recent study reported that DEXI expression is reduced in monocytes carrying the CLEC16A rs12708716 risk allele. 19 In our thymic tissue samples, we also observed reduced DEXI expression in CLEC16A risk carriers, but for the CLEC16A rs6498169 genotype. As rs12708716 and rs7206912 are in strong D 0 -LD with rs6498169 (Figure 1b) , a correlation to rs12708716 and rs7206912 could also be expected in our samples. Indeed, DEXI expression was lower in samples carrying the rs12708716 and rs7206912 risk alleles, although not significantly reduced. Interestingly, chromosome conformation-capture experiments performed by Davison et al. 19 proposed that a loop can be formed between the DEXI promoter region and a 20-kb region of intron 19 of CLEC16A (containing rs12708716), suggesting a potential mechanism for how intronic sequences within CLEC16A might affect expression of neighboring genes. Our findings together with the previously reported DEXI expression quantitative trait locus data for disease-associated CLEC16A SNPs and the finding of the close physical proximity of CLEC16A intron 19 and the DEXI promoter 19, 20 indicate that CLEC16A intron 19 harbors a regulatory region for DEXI in immune cells and highlights DEXI as an autoimmune candidate gene.
Although the function of DEXI is unknown, it has been shown that absence of Socs1 leads to aberrant thymocyte development and systemic inflammation in mice. 28 More specifically, Socs1 has shown to influence the Foxp3 þ CD4 þ T-regulatory cell differentiation in the thymus. 29 Interestingly, loss of Socs1 is also associated with increased differentiation of Th17 cells, a proinflammatory CD4 þ T-cell subset found in higher amounts in the peripheral blood of patients with active MS compared with healthy controls. 30, 31 The observed reduced SOCS1 expression in thymic samples harboring the CLEC16A risk alleles might affect thymocyte development and suggests a potential mechanism for development of autoimmune disease.
Correlation between CLEC16A expression and that of SOCS1 and DEXI has previously been observed in lymphoblastoid cell lines, but not in monocytes. 17, 19 As B30% of genes show discordant tissue-dependent regulation, 32 we investigated whether there were any correlations between the levels of the four selected genes in whole-blood and in thymic tissue samples. A linear regression analysis was performed for each pair-wise combination of CIITA, DEXI, CLEC16A and SOCS1gene expression levels. No correlations were found in the whole-blood samples (data not shown), whereas in the thymic tissue samples the expression levels of CLEC16A and DEXI (R 2 ¼ 0.27, Po0.001) as well as CLEC16A and SOCS1 (R 2 ¼ 0.63, Po0.0001) were found to be correlated. In addition, a significant correlation between DEXI and SOCS1 expression levels (R 2 ¼ 0.21, P ¼ 0.0041) was observed ( Table 1) . DEXI is reported to be upregulated in an adenocarcinoma alveolar epithelial cell line upon dexamethasone treatment. 25 This strong immunosuppressive drug also regulates SOCS1 expression in macrophages, 33, 34 suggesting a common regulation of SOCS1 and DEXI.
In conclusion, our data support the existence of a regulatory element in the CLEC16A region of chromosome 16p13, 17 which also influences the expression of DEX1 and SOCS1. These findings imply that DEX1 and SOCS1 may represent possible autoimmune candidate genes. The fact that several SNPs in the CLEC16A gene region have shown association to other autoimmune diseases in addition to MS [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] indicate common mechanisms between autoimmune diseases and the importance of further investigation of this genetic region.
MATERIALS AND METHODS

Subjects and genotyping
Thymic tissue samples from Norwegian children under the age of 13 undergoing corrective cardiac surgery (n ¼ 37) were collected in RNA later (Qiagen, Hilden, Germany) and peripheral whole-blood samples from healthy Norwegian individuals from the bone marrow donor registry (n ¼ 24) were collected on Tempus blood RNA tubes (Applied Biosystems, Foster City, CA, USA). 11, 35 The study was approved by the local ethical authorities, and informed consent was given either by the parents of the children or the patients/donors. SNP genotyping of the whole-blood and thymic tissue samples was performed in a previous study. 11 One of the thymic tissue samples was not successfully genotyped for the rs6498169 SNP.
Gene expression analysis RNA from whole blood was isolated using the Tempus spin RNA kit (Applied Biosystems) and RNA from thymic tissues was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) as described. 11, 35 RNA concentration, quality and integrity were verified by Nanodrop DN-1000 Spectrophotometer (Thermo Fisher Scientific Inc., Madison, WI, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Reverse transcriptase (RT) PCR was performed with 50 ng RNA using the Reverse Transcriptase Core kit (RT-RTCK) with random nonamer primers and the EuroScript reverse transcriptase (all from Eurogentec, Liege Science Park, Seraing, Belgium). A standard curve was generated for each Table 1 . Linear regression analysis of pair-wise comparison of CIITA, DEXI, CLEC16A and SOCS1 expression in thymic tissue samples
.0001* R 2 represents the correlation coefficient and P is uncorrected P-values; *, significant correlations.
RNA collection as a 1:2-fold dilution series (100-1.5625 ng) using a mixture of RNA for the specific collection. RT was performed using the GeneAmp PCR system 9700 thermo cycler (Applied Biosystems) for a one-step PCR reaction ( 
Statistical analysis
Correlation between gene expression levels and genotypes were assessed by two-sided Mann-Whitney U-test using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). For permutation analyses, a subset of 24 data points (equal to the number of data points in the whole-blood samples) from the thymic samples showing significant correlation between genotype and gene expression were randomly picked 1000 times, keeping the ratio in number between the groups equal to the ratio in the thymic samples. A two-sided Mann-Whitney U-test was performed on those data sets (R software, R core team). The median P-value of 1000 tests o0.05 was considered significant. Linear regression analysis of gene expression levels was performed using SPSS (IBM SPSS Statistics 19, Chicago, IL, USA). CLEC16A expression was correlated with the expression of the CIITA, DEXI and SOCS1 predictor genes, and pair-wise correlations between CIITA, DEXI and SOCS1 were also analyzed. Correlation coefficients (R 2 ) with P-values below 0.05 were considered significant.
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